Royalty Free Photo
UArizona Health Sciences Researchers Prepare First Potential Drug Therapy for Vascular Dementia for Clinical Trials
College of Medicine News

University of Arizona Health Sciences researchers are moving closer to conducting clinical trials on what would be the first therapeutic drug for vascular cognitive impairment and dementia (VCID), the second most common form of dementia after Alzheimer’s disease. Research by Meredith Hay, PhD, a UArizona professor of physiology, and member of the BIO5 Institute and the Evelyn F. McKnight Brain Institute, may offer a remedy for vascular dementia. To date, the U.S. Food and Drug Administration has not approved any drugs that specifically treat vascular dementia, which involves cognitive impairment caused by injuries – often stroke related – to the vessels supplying blood to the brain.